Antibody-based immunotherapy for malignant glioma.

Published

Journal Article (Review)

Conventional therapy for malignant glioma (MG) fails to specifically eliminate tumor cells, resulting in toxicity that limits therapeutic efficacy. In contrast, antibody-based immunotherapy uses the immune system to eliminate tumor cells with exquisite specificity. Increased understanding of the pathobiology of MG and the profound immunosuppression present among patients with MG has revealed several biologic targets amenable to antibody-based immunotherapy. Novel antibody engineering techniques allow for the production of fully human antibodies or antibody fragments with vastly reduced antigen-binding dissociation constants, increasing safety when used clinically as therapeutics. In this report, we summarize the use of antibody-based immunotherapy for MG. Approaches currently under investigation include the use of antibodies or antibody fragments to: (1) redirect immune effector cells to target tumor mutations, (2) inhibit immunosuppressive signals and thereby stimulate an immunological response against tumor cells, and (3) provide costimulatory signals to evoke immunologic targeting of tumor cells. These approaches demonstrate highly compelling safety and efficacy for the treatment of MG, providing a viable adjunct to current standard-of-care therapy for MG.

Full Text

Duke Authors

Cited Authors

  • Gedeon, PC; Riccione, KA; Fecci, PE; Sampson, JH

Published Date

  • August 2014

Published In

Volume / Issue

  • 41 / 4

Start / End Page

  • 496 - 510

PubMed ID

  • 25173142

Pubmed Central ID

  • 25173142

Electronic International Standard Serial Number (EISSN)

  • 1532-8708

International Standard Serial Number (ISSN)

  • 0093-7754

Digital Object Identifier (DOI)

  • 10.1053/j.seminoncol.2014.06.004

Language

  • eng